CA-ADVA
24.1.2023 18:01:38 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Brandywine Communications is using its OSA 5422 grandmaster clock to deliver a robust and feature-rich M-Code timing solution for use cases such as US Department of Defense applications. The new edge synchronization offering addresses the key requirements of military networks by providing enhanced positioning, navigation and timing (PNT) capabilities and improved resilience. Built on Oscilloquartz’s versatile timing technology with integrated M-Code capabilities, the solution is ideal for the most demanding military edge applications. It supports 1Gbit/s and 10Gbit/s interfaces, provides innovative GNSS assurance capabilities as well as backup through Oscilloquartz’s assured PNT (aPNT+™) technology, and meets the most stringent timing demands in an operationally efficient and cost-effective way.
“Our M-Code edge timing offering will be a game-changer for defense applications. Powered by ADVA’s OSA 5422 grandmaster clock, it meets the most urgent needs of military networks that require precise and reliable PNT information and delivers new levels of reliability and security. One key feature of the OSA 5422 is its long holdover and PTP backup, which enables it to maintain accurate timing even in the event of M-Code disruption. This is critical for pressurized defense networks that need to operate in a variety of difficult environments,” said Allen Ronk, president of Brandywine Communications. “Our solution features multi-source backup capabilities to ensure that M-Code outages do not disrupt synchronization. It also provides sync assurance capabilities that continually monitor the performance of the timing system and take immediate corrective action when needed.”
M-Code is an encrypted GPS signal used exclusively by the US military in defense applications that require precise and reliable synchronization. Resistant to jamming and spoofing, M-Code is an invaluable asset for defense organizations operating in challenging conditions. ADVA’s OSA 5422 grandmaster clock is now integrated with a highly reliable M-Code receiver that meets stringent frequency and phase synchronization needs and offers the best holdover performance of any edge device on the market. Also equipped with multi-band, multi-constellation GNSS receivers for when M-Code is not available, the device offers support for legacy interfaces such as BITS and IRIG, and features eight field-upgradeable 10Gbit/s ports and 1Gbit/s interfaces. The OSA 5422 is also environmentally hardened with hot-swappable modules and power supplies for easy field upgrades.
“As military applications demand increasingly precise and reliable PNT capabilities, the need for secure, jamming- and spoofing-resistant M-Code technology becomes ever more pressing. With its long holdover, multi-source backup capabilities, sync assurance capabilities, and other advanced features, our OSA 5422 is perfectly positioned to meet this demand,” commented Gil Biran, GM of Oscilloquartz, ADVA. “We’re excited to be working with Brandywine Communications as our strategic partner and to be bringing our innovation to defense applications that rely on precise and reliable PNT in the US and elsewhere. The market for military GPS receivers with M-Code capabilities is growing, as defense organizations seek to enhance their PNT capabilities and improve resilience. Together, we’re helping empower a whole new section of customers to benefit from the industry’s most agile synchronization toolkit.”
ADVA’s Oscilloquartz aPNT+™ and M-Code technology is being showcased at the Precise Time and Time Interval Systems and Applications Meeting (PTTI 2023) in Long Beach, California, from January 23 to 26. Attendees can visit the Oscilloquartz team at Brandywine Communications’ booth to learn about the platform’s ability to provide resilient and assured PNT services for military applications in line with the Department of Defense’s latest zero-trust strategy, and how the OSA 5422 supports both time-as-a-service (TaaS) and GNSS-backup-as-a-service (GBaaS).
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005723/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom